Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

Objectives

The primary objective is to determine the incidence of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. Incidence will be determined via patient-reported incidence following G-CSF administration.

Secondary objectives include determining the efficacy of loratadine for bone pain prevention as indicated by a decrease in incidence and a decrease in severity (questions 4 and 5 of the survey).

Inclusion criteria

• Receiving a G-CSF after the institution practice change
• Receiving a G-CSF for one of the following indications:
• Prevention/treatment of neutropenia along with treatment for leukemia or lymphoma
• Mobilization of hematopoietic progenitor cells
• Neutropenia prevention following autologous hematopoietic cell transplant
• Took loratadine per protocol with G-CSF administration
• Completed a survey

Exclusion criteria

• Taking daily antihistamines for allergies, asthma, or other indications, not including bone pain
• Taking daily NSAIDs, with the exception of aspirin, for chronic conditions
• Treatment for solid tumor cancers
• Receiving bone modifying agents for bone pain associated with metastatic disease or other chronic conditions